{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0020791\nAge: 62\nGender: Female\nSample ID: P-0020791-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Colon Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 60.0%\n=============\nDNA Variants:\nAPC c.847C>T (p.R283*) - in 46.00% of 697 reads\nBRCA2 c.8524C>T (p.R2842C) - in 19.00% of 420 reads\nKRAS c.35G>T (p.G12V) - in 33.00% of 625 reads\nPIK3CA c.1624G>A (p.E542K) - in 37.00% of 533 reads\nPPP2R1A c.547C>T (p.R183W) - in 39.00% of 869 reads\nSMAD2 c.1285C>T (p.Q429*) - in 55.00% of 266 reads\nSMAD3 c.799G>T (p.E267*) - in 70.00% of 858 reads\nCNA Data:\nNo CNA data found.\nStructural Variants:\nAPC - nan (DELETION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Colon Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"FOLFOX (FOLinic acid, Fluorouracil, Oxaliplatin)\",\n    \"Prior Treatment or Resistance Status\": \"No prior treatment specified\",\n    \"Genomic Features\": [\n      \"KRAS G12V mutation (resistance to EGFR inhibitors)\",\n      \"PIK3CA E542K mutation (potential sensitivity to PI3K inhibitors)\",\n      \"SMAD2 and SMAD3 truncating mutations (may influence TGF-beta pathway targeting)\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-drug-labels\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Colon Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"PARP inhibitors (e.g., Olaparib)\",\n    \"Prior Treatment or Resistance Status\": \"BRCA2 mutation (potential sensitivity)\",\n    \"Genomic Features\": [\n      \"BRCA2 c.8524C>T (p.R2842C) mutation indicating possible homologous recombination deficiency\"\n    ],\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approved-drug-labels\"\n  }\n}"
}